It’s Not Over Yet For Gossamer Bio Inc (NASDAQ: GOSS)

After Hours

The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Most recently, Yahoo Finance reported about the stock as it publicized that Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4).

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

Stocks Info

Gossamer Bio Inc is listed on the NASDAQ as a member of the Healthcare sector and is a part of the Biotechnology industry. The current market capitalization of Gossamer Bio Inc is $286.27M. A total of 1.53 million shares were traded on the day, compared to an average of 1.39M shares.

Insider Activity

Additionally, investors take into account insider trades when predicting how a stock will perform. During the recent three months, GOSS has seen 0 BUY and 0 SELL insider trades, representing the acquisition of 0 and the disposition of 0 shares. Over the last 12 months, there were 11 BUYs and 4 SELLs from insiders. Insiders purchased 1,841,772 shares during that period but sold 22,970.

In the most recent transaction, Milligan Sandra bought 32,000 shares of GOSS for 0.79 per share on Nov 15. After the transaction, the Director now owns 32,000 company shares. In a previous transaction on Nov 13, Giraudo Bryan bought 200,000 shares at 0.56 per share. GOSS shares that COO/CFO owns now total 380,010.

Among the insiders who sold shares, Aranda Richard disposed of 1,814 shares on Jun 22 at a per-share price of $1.29. This resulted in the Chief Medical Officer holding 197,574 shares of GOSS after the transaction. In another insider transaction, Giraudo Bryan bought 55,000 shares at $1.02 per share on Apr 04. Company shares held by the COO/CFO now total 125,990.

Though price targets are rarely accurate, they can exert some influence from time to time and were often accepted as valuable by the market. According to analysts who have offered 12-month price targets for GOSS in the last 3 months, the mean price target is $6.09 with high estimates of $15.00 and low estimates of $0.50. In terms of 52-week highs and lows, GOSS has a high of $1.91 and a low of $0.45.

As of this writing, GOSS has an earnings estimate of -$0.21 per share for the current quarter. EPS was calculated based on a consensus of 8 estimates, with a high estimate of -$0.17 per share and a lower estimate of -$0.29. The company reported an EPS of -$0.45 in the last quarter, which was 8.20% higher than expectations of -$0.49.

Balance Sheet Annually/Quarterly

A balance sheet is a report that shows the company’s assets and liabilities. In addition, it shows how much equity investors have invested in the company. Investors can determine the company’s prospects by calculating its financial ratios based on this information. GOSS’s latest balance sheet shows that the firm has $325.22M in Cash & Short Term Investments as of fiscal 2021. There were $185.24M in debt and $39.86M in liabilities at the time. Its Book Value Per Share was $0.46, while its Total Shareholder’s Equity was $121.46M.

Analysts Opinion

It may be riskier to trade before market opening and after market closing than during regular market hours. Since issuers often announce critical financial information outside regular trading hours. Extended-hours trading may result in wider spreads for particular securities due to lower liquidity and higher volatility. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for GOSS is Buy with a score of 4.33.

Most Popular

Related Posts